Page last updated: 2024-12-06

omega-aminocaprylic acid

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

8-aminooctanoic acid : An omega-amino fatty acid that is octanoic acid which carries an amino group at position 8. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID66085
CHEMBL ID196105
CHEBI ID143265
SCHEMBL ID35564
MeSH IDM0134285

Synonyms (45)

Synonym
8ac ,
nsc59019
1002-57-9
nsc-59019
8-aminocaprylic acid
.omega.-aminocaprylic acid
8-amino-octanoic acid
8-aminooctanoic acid, 99%
octanoic acid, 8-amino-
4E709DFA-3A0E-43BB-ABAC-B157B44A07F9
CHEMBL196105 ,
omega-aminocaprylic acid
omega-ac
8-aminooctanoic acid
CHEBI:143265
A800080
einecs 213-687-9
x8h8hft75v ,
unii-x8h8hft75v
nsc 59019
8-amino capylic acid
FT-0602038
AKOS015855191
BP-30141
SCHEMBL35564
nh2-(ch2)7-cooh
8-amino caprylic acid
8-aminooctanoic acid #
DTXSID00143007
mfcd00008245
J-000075
LMFA01100059
GS-6649
h-aoc(8)-oh
bdbm50485559
CS-W019464
SY043332
BP-13455
EN300-96214
Q27456865
S6082
HY-W018678
8-aminooctanoicacid
SY350681
PD123956

Research Excerpts

Pharmacokinetics

ExcerptReferenceRelevance
" Development of BB2r-targeted agents, based on the bombesin (BBN) peptide, has largely involved the use of the bifunctional chelate approach in which the linking group serves several key roles including pharmacokinetic modification."( Evaluation of the pharmacokinetic effects of various linking group using the 111In-DOTA-X-BBN(7-14)NH2 structural paradigm in a prostate cancer model.
Figueroa, SD; Garrison, JC; Hoffman, TJ; Naz, F; Rold, TL; Sieckman, GL; Sublett, SV; Volkert, WA, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (1)

RoleDescription
human metaboliteAny mammalian metabolite produced during a metabolic reaction in humans (Homo sapiens).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
medium-chain fatty acidAny fatty acid with a chain length of between C6 and C12.
omega-amino fatty acidAny fatty acid n atoms long having an amino substituent at position n (omega).
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Solute carrier family 15 member 2Rattus norvegicus (Norway rat)Ki7,900.00003.00006.47788.5000AID681124
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (5)

Assay IDTitleYearJournalArticle
AID681124TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT2-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
AID255581Percent inhibition of CD40 expression in BCL1 cells treated with 3 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID255583Percent inhibition of CD40 expression in BCL1 cells treated with 10 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID255579Percent inhibition of CD40 expression in BCL1 cells treated with 1 uM peptide nucleic acid (PNA)conjugate; n=32005Journal of medicinal chemistry, Oct-20, Volume: 48, Issue:21
Structure-activity relationship study on a simple cationic peptide motif for cellular delivery of antisense peptide nucleic acid.
AID681125TP_TRANSPORTER: inhibition of Gly-Sar uptake in PEPT1-expressing LLC-PK1 cells2000Pflugers Archiv : European journal of physiology, Sep, Volume: 440, Issue:5
Structural requirements for determining the substrate affinity of peptide transporters PEPT1 and PEPT2.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (12)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (8.33)18.7374
1990's3 (25.00)18.2507
2000's5 (41.67)29.6817
2010's3 (25.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.31

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.31 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index4.88 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.31)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]